Thai Pharmaceutical Association Views ART as Potential Opportunity
The Thai Pharmaceutical Association suggests that the ART agreement may have minimal impact on the domestic market, provided that US drug tax exemptions are maintained.
According to a report by Matichon Online, the Thai Pharmaceutical Association has evaluated the potential impact of the ART agreement on the local pharmaceutical industry. Industry representatives expressed a positive outlook, suggesting that the agreement could present new opportunities rather than significant threats to domestic drug manufacturers. A key factor in this assessment is the cost structure of American pharmaceutical products, which are reportedly ten times higher than those produced in Thailand. The association believes that as long as tax exemptions for US drugs remain in place, the competitive pressure on local Thai manufacturers will be minimal. For residents and expatriates in Thailand, this suggests that the local pharmaceutical market may remain stable in the near term, with domestic manufacturers continuing to provide cost-effective alternatives to imported medications. While the association views the current situation as manageable, the long-term implications of the ART agreement on drug pricing and availability remain to be fully confirmed as the policy landscape evolves. Stakeholders are advised to monitor official government announcements regarding trade regulations and pharmaceutical import policies to understand how these economic shifts might influence healthcare costs in the future.